Corcept Therapeutics (CORT) Fundamental Analysis: Revenue, Earnings & Valuation

0.85 / 10

Underperform

Fundamental assessment rates Underperform with a 0.8/10 quality score. Inventory and receivables turnover are modest, but income‑tax ratio, fixed‑asset turnover and PB‑ROE are weak, indicating constrained earnings and limited growth potential.

Analysis Checks(4/10)

Revenue-MV

Value-0.75

Score1/3

Weight49.27%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value12.79

Score1/3

Weight-11.32%

1M Return-1.40%

Inventory turnover ratio

Value1.03

Score2/3

Weight-5.86%

1M Return-0.66%

Accounts receivable turnover ratio

Value13.39

Score2/3

Weight-5.23%

1M Return-0.65%

PB-ROE

Value3.33

Score0/3

Weight38.21%

1M Return3.80%

Income tax / Total profit (%)

Value-49.94

Score1/3

Weight-4.79%

1M Return-0.59%

Fixed assets turnover ratio

Value332.56

Score1/3

Weight-9.79%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-5.90%

1M Return-0.73%

Cost of sales ratio (%)

Value1.70

Score3/3

Weight7.34%

1M Return0.79%

Asset-MV

Value-0.55

Score0/3

Weight48.06%

1M Return4.88%

Is CORT fundamentally strong?

CORT scores 0.85/10 on fundamentals and holds a Premium valuation at present. Backed by its 14.79% ROE, 13.09% net margin, 45.33 P/E ratio, 6.87 P/B ratio, and -29.63% earnings growth, these metrics solidify its Underperform investment rating.